TY - JOUR
T1 - Phosphate therapy in diabetic ketoacidosis
AU - Wilson, H. K.
AU - Keuer, S. P.
AU - Lea, Alfred
AU - Boyd, A. E.
AU - Eknoyan, G.
PY - 1982
Y1 - 1982
N2 - To determine the efficacy of phosphate replacement in the therapy for diabetic ketoacidosis (DKA), 44 patients were randomly assigned to three treatment groups: those who received no phosphate replacement, those who received 15 mmole of sodium phosphate at the fourth hour, or those who received 15 mmole of sodium phosphate at 2, 6, and 10 hours. All patients were treated with intravenous insulin injection (0.1 units/kg/hr), fluids, and potassium. Four hours after a 15-mmole sodium phosphate infusion, the serum phosphate level was 2.8 ± 0.8 mg/dL vs 2.1 ± 0.8 mg/dL in the control patients; however, this dose was insufficient to maintain the serum phosphate level at 16 and 24 hours. Forty-five millimoles of phosphate prevented severe hypophosphatemia in all but one patient and produced substantially higher phosphate levels at 8, 16, and 24 hours. Phosphate therapy did not affect the duration of DKA, dose of insulin required to correct the acidosis, abnormal muscle enzyme levels, glucose disappearance, or morbidity and mortality. Although theoretically appealing, phosphate therapy is not an essential part of the therapy for DKA in most patients.
AB - To determine the efficacy of phosphate replacement in the therapy for diabetic ketoacidosis (DKA), 44 patients were randomly assigned to three treatment groups: those who received no phosphate replacement, those who received 15 mmole of sodium phosphate at the fourth hour, or those who received 15 mmole of sodium phosphate at 2, 6, and 10 hours. All patients were treated with intravenous insulin injection (0.1 units/kg/hr), fluids, and potassium. Four hours after a 15-mmole sodium phosphate infusion, the serum phosphate level was 2.8 ± 0.8 mg/dL vs 2.1 ± 0.8 mg/dL in the control patients; however, this dose was insufficient to maintain the serum phosphate level at 16 and 24 hours. Forty-five millimoles of phosphate prevented severe hypophosphatemia in all but one patient and produced substantially higher phosphate levels at 8, 16, and 24 hours. Phosphate therapy did not affect the duration of DKA, dose of insulin required to correct the acidosis, abnormal muscle enzyme levels, glucose disappearance, or morbidity and mortality. Although theoretically appealing, phosphate therapy is not an essential part of the therapy for DKA in most patients.
UR - http://www.scopus.com/inward/record.url?scp=0020062376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020062376&partnerID=8YFLogxK
U2 - 10.1001/archinte.142.3.517
DO - 10.1001/archinte.142.3.517
M3 - Article
C2 - 6802095
SN - 0003-9926
VL - 142
SP - 517
EP - 520
JO - Archives of Internal Medicine
JF - Archives of Internal Medicine
IS - 3
ER -